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Accumulating evidence suggests that neural-immune interactions are involved in the development of painful chemotherapy-
induced peripheral neuropathy, particularly through the increased release of proinﬂammatory cytokines. The purpose of this
study was used to evaluate levels of interleukin [IL]-6 and IL-6 receptors in women with breast cancer after the conclusion of
chemotherapy who either had painful symptoms of chemotherapy-induced peripheral neuropathy (CIPN group, N = 20) or
did not experience CIPN symptoms (Comparison group, N = 20). CIPN participants had signiﬁcantly higher levels of IL-6
and soluble IL-6R (sIL-6R) compared to women without CIPN symptoms (P<. 001 for both). In addition, soluble gp130, which
blockstheIL-6/sIL-6Rcomplexfrombindingtogp130withinthecellularmembrane,wassigniﬁcantlylower(P<. 01).Circulating
concentrations of sIL-6R were inversely correlated with the density of IL-6R on the cell surface of monocytes in the total sample
(r =− .614,P = .005). These ﬁndings suggest that IL-6 transsignaling may be an important biological mechanism associated with
the persistence of painful CIPN symptoms, with potential implications for symptom management and research.
1.Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) can
be a debilitating and often painful consequence of cancer
treatment [1–4]. It is estimated that 30–40% of cancer
patients experience CIPN, with the incidence varying based
on the chemotherapeutic agent used, treatment intensity,
including dose and duration of administration, cumulative
dose, overall duration of therapy, and coadministration of
multiple agents [5].
Chemotherapeutic agents most often associated with
CIPN include the platinum-based compounds cisplatin, car-
boplatin, and oxaliplatin; plant alkaloids vincristine and vin-
blastine; taxanes such as paclitaxel and docetaxel; eopothilo-
nes such as ixabepalone; other agents including thalidomide,
lenolidamide,andbortezomib[4].Theprecisemechanismof
neuronal injury is thought to vary by agent [6]. For instance,
plant alkaloids and taxanes cause direct axonal injury and
demyelinization by blocking tubulin polymerization, which
leads to impaired axoplasmic transport due to microtubule
clumping. In contrast, platinum analogs reduce axonal
transport and cause apoptosis of dorsal root ganglion cells
[7, 8].
CIPN can include alterations in sensory, motor, and/or
autonomic function [9]. Sensory changes can include numb-
ness, tingling, hyperesthesia, loss of vibratory perception,
and burning pain. Accumulating evidence suggests that
inﬂammatory activation modulated through the increased
release of proinﬂammatory cytokines is a key biological
mechanism associated with painful neuropathies [10–12].
1.1. Chemotherapy-Induced Peripheral Neuropathy in Women
with Breast Cancer. Women with breast cancer are often
exposed to chemotherapeutic agents that can cause symp-
toms of CIPN [5]. For most women, painful CIPN symp-
toms initially manifest during treatment and subside after
the cessation of chemotherapeutic agents [6]. However,
approximately 15–20% of women with BCA will experience
persistent painful CIPN, which is of particular importance
in this patient population who are typically young and2 Nursing Research and Practice
constitute the largest group of cancer survivors in the United
States [13]. Multiples studies have shown that while women
with BCA perceive beneﬁt from their cancer treatment, they
report problems with persistent painful CIPN, functioning,
and global quality of life (QOL) [14–16]. Thus, identifying
the factors that inﬂuence CIPN symptoms and QOL is of
particular importance in this patient population.
1.2. Biological Factors Implicated in Chemotherapy-Induced
Peripheral Neuropathy. When peripheral nerve damage
occurs due to the exposure of neurotoxic chemicals, cir-
culating immune cells, as well as resident immune cells of
the nerve ﬁbers, begin to release proinﬂammatory cytokines
into the area of injury [17]. As blood-borne immune cells
inﬁltrate into the damaged region, functional changes occur
such as endoneural swelling and breakdown of the blood-
nerve barrier [18], allowing direct exposure of neural tissue
to inﬂammatory mediators. Elevated levels of proinﬂamma-
tory cytokines such as interleukin [IL]-1, IL-6, and tumor
necrosis factor[TNF]-alpha are found afternerve injury, and
neuropathic pain is attenuated by suppressing the release of
these molecules [19–21].
IL-6 in particular has been shown to play a large role
in the inﬂammatory process following nerve injury and
has been implicated in the initiation and maintenance
of neuropathic pain [22–24]. However, IL-6 activity is
dependent upon the distribution of receptors on speciﬁc cell
types to which it can bind. The distribution of membrane-
bound (IL-6R) receptors, to which IL-6 can bind directly,
is fairly limited throughout the body, existing mainly on
hepatocytes and certain subsets of leukocytes. In contrast,
IL-6 can complex with soluble receptor IL-6R (sIL-6R) to
activate the signal transducing receptor, gp130, which is
expressed nearly ubiquitously among all cell types [25, 26].
This means that cells capable of responding to IL-6 alone are
restricted to IL-6R + cells whereas virtually all cells respond
to the IL-6/sIL-6R complex. Unlike other soluble cytokine
receptors that inhibit cytokine signaling, such as those for
TNF-alpha,sIL-6RprolongsthehalflifeofIL-6andampliﬁes
itsinﬂammatoryactionsbyallowinggp130+cellstorespond
to IL-6 [27, 28]. Soluble gp130 (sgp130) can inhibit IL-6
activity by binding to the sIL-6R/IL-6 complex thereby
preventing its attachment with gp130 within the cellular
membrane. Thus, a higher number of sIL6-R receptors could
increase IL-6 activity, thereby increasing inﬂammation and
sensitization of the peripheral nerves, whereas higher sgp130
levels could impair IL-6 activity.
It was recently reported that women with breast cancer
(BCA) who have symptoms of CIPN are three times more
likely to suﬀer from persistent neuropathic pain compared
to women who do not experience CIPN [29]. Activation of
the inﬂammatory cascade may represent a signiﬁcant factor
that determines the presence of painful CIPN symptoms
and the transition to neuropathic pain. The identiﬁcation of
speciﬁc biological mechanisms involved in the manifestation
of painful CIPN and reduced QOL may provide a means
to monitor for those who may be at risk before symptoms
occur and QOL declines and may provide a potential thera-
peutic target to prevent or treat persistent CIPN symptoms.
Therefore, the primary aim of this study was to examine
the levels of IL-6 and IL-6 receptors (IL-6R and sIL-6R) in
women who reported either painful CIPN symptoms or no
CIPN symptoms following BCA treatment. The secondary
aimwastoexploretherelationshipsamongbiologicalfactors
and health-related QOL.
2.MaterialsandMethods
A two-group comparison design was used to evaluate IL-6
and IL-6 receptors in women with BCA who either reported
painful symptoms of CIPN or who had no symptoms of
CIPN after chemotherapy. This study was approved by the
Institutional Review Board residing over the recruitment
sites and written informed consent was obtained from all
participants.
2.1. Setting and Sample. Recruitment took place at three
oncology clinics located in the northwest region of the
United States. Fliers about the study were posted at each
study site, which asked potential participants with painful
CIPN symptoms to contact the Primary Investigator (PI)
if they were interested in learning about the study. In
addition, research nurses at each site approached potential
participants about the study, and if interested, they were
contacted by the PI. Women diagnosed with BCA were
eligible for participation if they met the following criteria:
(1) theywere between 6 and 12 months after diagnosis
of grade II-III BCA and had completed systemic adjuvant
cancer therapy, (2) had no history of other cancer, diabetes,
cardiovasculardisease,psychologicaldisorder(majordepres-
sion, anxiety, schizophrenia, or bipolar disorder), immune-
basedcomorbidity(HIV,lupus,andmultiplesclerosis),renal
disease, alcoholism, or peripheral neuropathy before the
administration of systemic chemotherapy, (3) absence of
current or recent infection, immunization, hypothyroidism,
or vitamin deﬁciency, (4) and were proﬁcient in English.
2.2. Materials
2.2.1. Demographics. Demographic information consisted of
interval, categorical, and continuous variables, including:
age, race, ethnicity, marital status, level of education, past
medical history, medication prescribed and OTC usage, and
socioeconomic status.
2.2.2. Pain. The Short-Form McGill Pain Questionnaire
(MPQ-SF) is a well-established self-report measure that
entails ﬁfteen verbal descriptors of sensory and aﬀective
dimensions of pain, a present pain intensity scale, and the
evaluative overall intensity of total pain experience scale
[30]. Subjects are asked to rate the verbal descriptors (none-
mild-moderate-severe)anditemsaresummedtoprovidethe
total pain rating index (score ranges from 0 to 45). Present
pain intensity is measured by a 100-mm visual analog scale
(VAS); patients are asked to place an “X” on the line from
“no pain” to “worst possible pain”. The overall intensity
scale is categorical ((0) no pain; (1) mild; (2) discomforting;Nursing Research and Practice 3
(3) distressing; (4) horrible; (5) excruciating). Patients are
askedtoplaceacheckmarknexttothedescriptorthatreﬂects
their overall intensity of the total pain experience. Reliability
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0.87 [31].
2.2.3. Quality of Life. QOL was measured with the Medical
Outcomes Short-Form (SF-36) version 2. The SF-36 is
the most widely used health-related QOL instrument in
the world [27]. The SF-36 measures eight health concepts:
(1) limitations in physical activities because of health prob-
lems; (2) limitations in social activities because of physical
oremotional problems;(3)limitations inusualroleactivities
becauseofphysicalhealthproblems;(4)bodilypain;(5)gen-
eral mental health (psychological distress and well-being);
(6) limitations in usual role activities because of emotional
problems; (7) vitality (energy and fatigue); (8) general health
perceptions. All items are scored using Likert scales so that
a higher score reﬂects a more favorable health outcome. The
SF-36isscoredsothatallscalesareonthesamemetric,where
50 is the mean for the US general population and 10 is the
standard deviation. Norm-based scoring equates all scores,
so scores above 50 are better than the general population
average for all scales, while scores below 50 are worse. Test-
retest reliability of the SF-36 is reported to be high (0.85)
while internal consistency (α = 0.88 and 0.95) is good
[31].
2.2.4. IL-6 and IL-6 Receptor Measurements. Serum samples
were separated according to standard procedures and stored
at −70
◦C for batch testing. Serum levels of IL-6, soluble
IL-6R, and soluble gp130 were measured in triplicate using
Quantikine High Sensitivity Immunoassay kits (R&D Sys-
tems, Minneapolis, MN). Analyte capture was carried out in
100μLofserumincubated2hoursatroomtemperaturewith
constantshaking.Theplateswerethenwashedandincubated
with conjugate antibody 2 hours at room temperature. The
plates were washed again and incubated with substrate for 1
hour, ampliﬁer for 30 minutes, and stop solution. All labo-
ratory procedures and quality control measures were carried
out according to the manufacturer’s instructions. The intra-
assay precision of all tests was less than 8%; while interassay
precision was less than 9%. IL-6 sensitivity = 0.04pg/ml; sIL-
6R sensitivity = 6.5pg/mL; sgp130 sensitivity = 0.08ng/mL.
When circulating sIL-6R levels rise, there is a decrease in
the expression of cellular CD126 (IL-6R) due to cytokine-
induced receptor shedding [32]. In order to examine
the association between receptor shedding [of IL-6R]
and sIL-6R levels, the density of IL-6R on monocytes
(CD3−/CD126+/CD14+) was analyzed. This cell type was
selected because monocytes remain elevated for a prolonged
period of time after immune activation as opposed to
neutrophils and lymphocytes, which are quickly cleared
away and exhibit a less robust response to increased IL-6
levels [32]. Fluorescence-conjugated antibodies were used to
identify IL-6R receptors (R&D Systems, Minneapolis, MN).
Blood specimens were collected in heparinized vacutainers
and Ficoll (R&D Systems, Minneapolis, MN) density gradi-
ent was used to separate peripheral blood mononuclear cells
(PBMCs). Following this, PBMCs were cultured in RPMI
1640 +10% fetal bovine serum at 37
◦Ci n5 %C O 2. PBMCs
werestimulatedwith10ng/mLofIL-6,andIL-6Rcellsurface
expression was assessed 12 hours later. Cells were analyzed
by ﬂow cytometry (FACScan, BD Immunocytometry, San
Jose,CA)usingFITC-conjugatedanti-CD3toexcludeTcells,
phycoerythrin-conjugated anti-CD126 (IL-6R), and PC5-
conjugated anti-CD14 to identify monocytes.
2.3. Procedures. After explaining the details of the study and
screening potential participants for inclusion and exclusion
criteria, an assessment appointment was made. Participants
who reported having persistent painful peripheral neu-
ropathy that started after the initiation of chemotherapy
composed the CIPN group (N = 20) while those who
reported having no symptoms of peripheral neuropathy
during or after chemotherapy made up the comparison
group (N = 20). Recruitment continued until there were 20
participants in each group.
All assessments were scheduled within the same 2-hour
time period in the morning (8–10AM) to control for diurnal
variations in immune parameters. Participants were asked
to refrain from consuming food, drinking alcohol and/or
caﬀeine, using tobacco, taking nonprescription medication,
and engaging in strenuous exercise during the 12-hour
period before their appointment. At the appointment, a
sensory and motor exam was conducted by a clinician
trained in neurosensory testing in order to classify the grade
of CIPN or verify the absence of symptoms. Participants
were then asked to complete the study questionnaires and
have their blood drawn (20ml) for analysis of IL-6 and IL-
6 receptors. Blood was drawn using a standard venipuncture
protocol and collected into one serum separator vacutainer
tube, and one heparinized vacutainer tube. After the blood
draw, the vacutainers were placed on ice and transported
directly to the laboratory for processing.
2.3.1. Data Analysis and Interpretation. All data was entered
into SPSS version 16.0 (Chicago, IL). Shapiro-Wilk’s test
of normality was performed. The cytokine data, which was
not normally distributed, were transformed logarithmically
and retested to ensure normal distribution before analysis
by univariate analysis of variance (ANOVA). Further analysis
using the Levene test showed equality of variances between
groups after logarithmic transformation. The primary aim
of the study, to examine the levels of IL-6 and IL-6 receptors
(IL-6R and sIL-6R) in women who reported either painful
CIPN symptoms or no CIPN symptoms following BCA
treatment, was analyzed using independent t-tests with
Bonferroni corrections set at the 0.05 level of signiﬁcance.
Analyses of covariance controlled for possible confounders
in comparisons between the painful CIPN and Comparison
group. Covariates included age, body mass index, time
postdiagnosis, and treatment modality. The secondary aim,
to explore the relationships among biological factors and
QOL, was analyzed using Pearson correlation coeﬃcients
with signiﬁcance set at the 0.05 level (2-tailed).4 Nursing Research and Practice
3. Results
The study sample characteristics can be found in Table 1.
Both groups were composed of Caucasian, non-Hispanic
participants, with grade II-III BCA who had surgical tumor
resection of the breast with subsequent chemotherapy treat-
ment. The mean time since diagnosis for the CIPN group
was 8.2 months and 9.1 months for the Comparison group.
The mean body mass index (BMI) of the CIPN group was
29.8 (±5.2) and 28.4 (±4.9) in the Comparison group.
All participants received a combination chemotherapeutic
regimen. There were no signiﬁcant diﬀerences between
groups in terms of age, education, income level, BMI, or
comorbidities.Themostcommoncomorbiditieswerehyper-
tension, osteoporosis, and seasonal allergies.
AllCIPNparticipantswereclassiﬁedasgrade2or3using
the National Cancer Institute (NCI) Toxicity Criteria. The
CIPN participants rated their pain using the MPQ-SF. The
sensory aspects of pain had a mean score of 9 (±3) with
“hot burning” being the most common description selected.
Aﬀective components of pain had a mean score of 3 (±1.3)
with “tiring-exhausting” being selected most often. The total
pain rating index had a mean of 11.6 (±4.3) with a present
pain intensity score of 57 (±14) out of 100. The evaluative
overall intensity of total pain experience had a mean score of
2( ±1.0), reﬂecting the perception of the pain experience as
“discomforting”.
Interleukin-6 (Figure 1) and soluble IL-6R (sIL-6R,
Figure 2) levels were signiﬁcantly higher in the painful
CIPN group compared to women without CIPN symptoms
(comparison group) (IL-6, 2.43 versus 92pg/mL; t(38) =
−5.6, P<. 001; sIL-6R, 41.6 versus 30.2ng/mL; t(38) =
−5.1, P<. 001, resp.). In addition, soluble gp130 (Figure 3),
whichblockstheIL-6/sIL-6Rcomplexfrombindingtogp130
within the cell membrane, was signiﬁcantly lower in the
CIPN group compared to women without CIPN symptoms
(sgp130, 228.3 versus 350.8ng/mL; t(38) = 4.2, P<. 01).
Relationships among pain and the biological factors are
shown in Table 2.
The CIPN group had signiﬁcantly lower levels of IL-6R
on CD14+ cells (CD126/CD14 percentage of positive cells:
29% versus 42%; t(38) = −2.26, P = 0.03). Diﬀerences in
these biomarker concentrations remained signiﬁcant after
controlling for age, BMI, number of comorbidities, and time
postdiagnosis in an analysis of covariance. Elevated levels of
sIL-6R can cause cytokine-induced receptor shedding, lead-
ing to decreased cell-surface expression of IL-6R. Consistent
with this, monocyte cell-surface expression of IL-6R was
negatively correlated with circulating levels of sIL-6R in the
total sample (r =− .614, P = .005).
The CIPN participants scored signiﬁcantly lower on
all subscales of the SF-36 Health Survey except the “role
emotional” subscale compared to the women without CIPN
symptoms (data not shown; all Ps < .002). Signiﬁcant
relationshipswereidentiﬁedbetweenthebiologicalmeasures
and QOL subscales as shown in Table 3.L e v e l so fI L - 6
and sIL-6R were negatively correlated with general health,
physical functioning, role functioning, social functioning,
bodily pain, vitality, and mental health. Higher levels of
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Figure 1: Mean levels of serum interleukin [IL]-6 in women with
painful CIPN (N = 20) and women without CIPN symptoms
(Comparison Group, N = 20). Dots represent mean value of
Interleukin [IL]-6 measured in serum; error bars represent 95% CI.
Mean (SD), [Range] of the painful CIPN group: 2.43 (1.7)pg/mL
[1.3–3.8]; Comparison group: 0.92 (0.6)pg/mL [0.4–1.5]. Inde-
pendent t-test with Bonferroni correction performed to examine
diﬀerence between groups: (t(38) = −5.6, P<. 001).
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Figure 2: Mean levels of serum Soluble IL-6R in women with
painful CIPN (N = 20) and women without CIPN symptoms
(Comparison Group, N = 20). Dots represent mean value of
soluble IL-6R (sIL-6R) measured in serum; error bars represent
95% CI. Mean (SD), [Range] of the Painful CIPN group: 41.6
(9.7)ng/mL[31–54];Comparisongroup:30.2(5.8)ng/mL[22–39].
Independent t-test with Bonferroni correction performed to exam-
ine diﬀerence between groups: (t(38) = −5.1, P<. 001).
pain are reﬂected as lower scores on the SF-36 bodily pain
subscale. Levels of sgp130 were positively correlated with
most QOL subscales.
4. Discussion
The BCA participants with painful CIPN in this study had
signiﬁcantly higher levels of circulating IL-6 and sIL-6R than
participants without CIPN (Comparison group). Consistent
with a potential inﬂammatory basis for painful CIPN symp-
toms via increased IL-6 transsignaling, elevated levels of sIL-
6Rwereaccompaniedbyasigniﬁcantreductioninmonocyte
cell-surface expression of IL-6R. The density of IL-6R on theNursing Research and Practice 5
Table 1: Sample Characteristics.
Demographic variable Chemotherapy-induced peripheral neuropathy group (N = 20) Comparison group (N = 20)
Age [mean ± SD(range)] 56.8 + 6.6 years (42–65) 53.4 ± 5.6 years (43–65)
Marital status Married 12 (60%) Married 11(55%)
Divorced 5 (25%) Divorced 7 (35%)
Widowed 3 (15%) Widowed 2 (10%)
Education High school 11 (55%) High school 10 (50%)
College 5 (25%) College 7 (35%)
Postgraduate 4 (20%) Postgraduate 3 (15%)
Income level < $50K/year 6 (30%) < $50K/year 7 (35%)
$50–74K/year 6 (30%) $50–74K/year 6 (30%)
> $75K/year 8 (40%) > $75K/year 7 (35%)
Tobacco Use Never 16 (80%) Never 15 (75%)
Current or past use 4 (20%) Current or past use 5 (25%)
Comorbid conditions 0 conditions 7 (35%) 0 conditions 8 (40%)
1 condition 8 (40%) 1 condition 10 (50%)
2 conditions 4 (20%) 2 conditions 1 (5%)
3 or more conditions 1 (5%) 3 or more conditions 1 (5%)
Independent t-tests were used to analyze demographic data. There were no signiﬁcant diﬀerences between the painful CIPN and Comparison groups on any
of the demographic or treatment-related variables.
Table 2: Pearson correlation coeﬃcients among biological measures and pain perception.
IL-6 (pg/mL) sIL-6R (ng/mL) sgp130 (ng/mL)
Pain (total rating index) .519
∗∗ .762
∗∗ −.825
∗∗
IL-6 (pg/mL) 1 .613
∗∗ −.801
∗∗
sIL-6R (ng/mL) .613
∗∗ 1 −.692
∗∗
sgp130 (ng/mL) −.801
∗∗ −.692
∗∗ 1
∗∗P<. 01.
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Figure 3: Mean levels of serum soluble gp130 in women with
painful CIPN (N = 20) and women without CIPN symptoms
(Comparison Group, N = 20). Dots represent mean value of
soluble gp130 (sgp130) measured in serum; error bars repre-
sent 95% CI. Mean (SD), [Range] of the Painful CIPN group:
228.3 (112.7)ng/mL [198–263]; Comparison group: 350.8 (119.9)
ng/mL [290–407]. Independent t-test with Bonferroni correction
performed to examine diﬀerence between groups: (t(38) = 4.2,
P<. 01).
cell-surface of monocytes was also inversely correlated with
circulating levels of sIL-6R in the total sample (r =− .614,
P = .005).Furthermore,IL-6andsIL-6Rlevelswereinversely
correlated with most health-related QOL categories. These
ﬁndings suggest that painful CIPN symptoms and reduced
QOL are linked with activation of gp130 via the IL-6/sIL-
6R complex as opposed to the more restricted mechanism of
IL-6bindingdirectlytoitsmembrane-boundreceptor,IL-6R
[33].
Rencently, Andratsch et al. [34] reported that knock-
out mice lacking gp130 selectively in nociceptive neurons of
the dorsal root ganglion did not show behaviors consistent
with inﬂammatory-induced hyperalgesia when exposed to
noxious heat. Their ﬁndings indicate that gp130 expressed
in nociceptive primary aﬀerents required for the devel-
opment of pathological pain and hyperalgesia. Increased
levels of IL-6 and sIL-6R may therefore increase the risk of
experiencing CIPN through activation of gp130 on sensory
nerves.
When the peripheral nerve is damaged, immune-mod-
ulating cells, such as lymphocytes and macrophages, release
proinﬂammatory cytokines in order to home other immune
cells to the area of injury. These cells then inﬁltrate through
the blood-nerve barrier, exposing the injured tissue to a
host of inﬂammatory mediators [35]. Kiguchi and col-
leagues [36] recently demonstrated that repeated vincristine
administration causes an increase in invading peripheral
macrophage-derived IL-6 expression. When a neutralizing
antibody of IL-6 was injected into the area surrounding6 Nursing Research and Practice
Table 3: Pearson correlation coeﬃcients among biological measures and quality of life.
GH PF RF RE SF BP V MH
IL-6 (pg/mL) −.614
∗∗ −.724
∗∗ −.686
∗∗ −.062 −.374
∗ −.815
∗∗ −.509
∗∗ −.418
∗∗
sIL-6R (ng/mL) −.551
∗∗ −.526
∗∗ −.531
∗∗ −.136 −.386
∗ −.687
∗∗ −.358
∗ −.419
∗∗
sgp130 (ng/mL) .796
∗∗ .733
∗∗ .782
∗∗ .124 .478
∗∗ .850
∗∗ .511
∗∗ .503
∗∗
SF-36 Health Survey Subcategories; GH: general health; PF: physical functioning; RF: role functioning; RE: role emotional; SF: social functioning; V: vitality;
MH: mental health; ∗P<. 05, ∗∗P<. 01.
the sciatic nerve, it suppressed the development of vin-
cristine-inducedmechanicalallodynia.Thus,peripheralIL-6
may be an important factor involved in the pathophysiolog-
ical changes that cause painful CIPN symptoms. Increased
levels of inﬁltrating macrophages were also observed after
administration of paclitaxel [37], which was subsequently
linked with increased expression of matrix metalloproteinase
(MMP)-3, another factor inﬂuenced by proinﬂammatory
cytokine concentrations [38].
Additional cytokines may also be involved in the cascade
ofeventsleadingtopainfulCIPN.Arecentstudyinvestigated
mRNA levels of proinﬂammatory cytokines interleukin-2
(IL-2) and tumor necrosis factor-alpha (TNF) as well as
anti-inﬂammatory cytokines IL-4 and IL-10 among patients
withpainful neuropathy, nonpainful neuropathy andcontrol
participants [12]. Patients with painful neuropathy had a
two-fold increase in IL-2 and TNF, while patients with
nonpainfulneuropathyhadsigniﬁcantlyhighermRNAlevels
of IL-4 and IL-10. This study supports the hypothesis that
interactions between pro- and anti-inﬂammatory cytokines
are important for understanding the pathophysiological
changes associated with pain. While it is unlikely that IL-
6 activity is the only factor determining the presence of
painful CIPN symptoms, it may predispose individuals to
the biological interactions that result in the release of pain-
inducing substances. Clearly, to determine the signiﬁcance
of IL-6 activity and other cytokine interactions on painful
CIPN symptoms, further research is needed to characterize
a broad spectrum of immune factors over the treatment
trajectory. Studies that are able to control for the type of
chemotherapeutic agent administered are especially needed,
as it is possible that the induction of various mechanisms
thatleadtoelevatedlevelsofproinﬂammatorycytokinesmay
account for the variability in CIPN symptoms and health-
related QOL [39].
In the present study, participants with painful CIPN had
signiﬁcantly lower QOL scores compared to the Comparison
group. This ﬁnding is consistent with past research [40].
A recent study conducted among 6000 adults compared
QOL among people with and without chronic pain [41].
The pain group was subdivided into a chronic neuropathic
pain group (N = 241) and a chronic pain group (N =
1179).Chronicneuropathicpainwasassociatedwithseverely
reduced functioning in all aspects of daily activities and on
every dimension of QOL measured by the SF-36 Health
Survey. Even after adjusting for age and severity of pain, the
health and daily activity in chronic neuropathic pain was
poorer as compared to the chronic pain group or no-pain
group. In the present study, IL-6 and sIL-6R were negatively
correlated with most QOL subcategories, suggesting that
increased IL-6 activity is involved in CIPN-related QOL
impairments.
The results of the present study provide some evidence
that IL-6 and sIL-6R may be potential therapeutic targets
for painful CIPN. Clinical trials using neutralizing anti-
IL-6R antibody in patients with rheumatoid arthritis and
inﬂammatory pain have been promising, with signiﬁcant
reductions in pain perception and other inﬂammatory-
related symptoms in patients receiving anti-IL-6R antibody
[42, 43]. Notably, these agents work by inhibiting IL-
6R directly while preserving levels of sgp130. While more
research is needed to determine whether these agents will be
eﬀective in ameliorating CIPN symptoms, it provides hope
that a treatment may be found.
Nurses providing care to patients who are receiving
chemotherapeutic agents and other immune-modulating
medications can play a key role in recognizing potential
cytokine-related symptoms. The presence of cooccurring
symptoms (pain, fatigue, depression) associated with proin-
ﬂammatory cytokines has been reported [10, 33]. Nursing
research focused on identifying patients at risk of experienc-
ing painful CIPN and reduced QOL may wish to consider
including other symptoms, such as depression and fatigue,
which are known to be inﬂuenced by cytokine concentra-
tions, particularly IL-6. Ultimately, a deeper understanding
of the biological interactions that inﬂuence symptoms of dis-
ease and/or treatment is needed to enable the development
of strategies to identify patient at risk of poor outcomes and
eﬀective nursing interventions that will improve symptom
management and QOL in women with BCA.
4.1. Limitations. This study had several limitations that
need to be discussed, most notable being the small sample
size which included an all white, non-Hispanic population,
and the cross-sectional design with only one measurement
time-point. Although the main goal of the study was to
examine the concentrations of IL-6 and IL-6 receptors across
BCA-treatment groups, the diﬀerences in chemotherapeutic
protocols or other adjunctive treatment may have aﬀected
these results. For instance, it was recently reported that
women receiving taxanes were more than twice as likely to
develop CIPN, whereas women receiving platinum-taxane
combination therapy were more than three times as likely
to develop CIPN compared to women who did not receive
chemotherapy [44]. In addition, measurement of other acute
phase proteins, such as c-reactive protein (CRP), would
have strengthened the study by providing a quantitative
functionalevaluationoftheresultingIL-6activity.SinceCRPNursing Research and Practice 7
measurement was not a part of the original study design,
ﬁnancial constraints prohibited its inclusion.
The study may also be criticized for the analysis of cell-
surface IL-6R, which was restricted to a speciﬁc cell type
(monocytes) instead of including neutrophils or lympho-
cytes. Monocyte cell-surfaceIL-6R was selected for this study
because this cell type exhibits a sustained response after
immune activation, the mean time of CIPN symptoms was
8.2–9.1 months, and alterations in the number of monocyte
IL-6R receptors has been associated with other negative
symptoms in BCA populations [33]. Although cytokine
measurements and ﬂow cytometry data were performed
on serum and leukocytes puriﬁed from blood representing
overall IL-6 production and secretion from all cell types, the
major source of soluble IL-6R in persistent inﬂammation
is from monocytes [12, 25] whereas neutrophils and lym-
phocytes are primary sources during the acute inﬂammatory
response [27]. As a plausible cause of persistent CIPN
symptoms, chronic inﬂammation in this patient population
was evaluated by changes in IL-6 activity through the loss
of cell-surface IL-6 on monocytes, but this does not infer
that neutrophils and lymphocytes are not involved. Future
research may consider including cell-surface IL-6R on all
leukocyte cell types so that the role of acute versus chronic
inﬂammatory activation on CIPN outcomes may be better
understood.
All participants in the study were evaluated by an expe-
rienced clinician trained in neurosensory testing and were
graded for symptoms of CIPN according to the NCI Toxicity
Criteria. However, other measures for subjectively rating
CIPN symptoms are now available, which may be more
accurate in determining the eﬀect of CIPN on functioning
compared to a clinician’s assessment [45, 46]. The use of
these instruments should be considered both in the clinical
setting and in future CIPN research.
Inaddition, becausethisstudywasexploratoryinnature,
no cause-eﬀect relationship can be implied. Thus, although
elevated IL-6 activity was found among participants with
painful CIPN, it remains a potential mechanism involved in
the development of painful CIPN symptoms. However, not-
ing the accumulating evidence in pain research concerning
the role of cytokines in immune activation and the resultant
cascade of events that lead to pain, the role of increased IL-6
and soluble IL-6 receptors in women with persistent painful
CIPN and reduced health-related QOL warrants further
consideration.
5. Conclusions
Women with painful CIPN had signiﬁcantly higher levels
of IL-6 and sIL-6R, and signiﬁcantly lower levels of sgp130
and monocyte cell-surface IL-6R than women without
symptoms of CIPN after BCA treatment. Although no causal
relationship can be implied, the results of this study suggest
an inﬂammatory basis for painful CIPN symptoms among
women with BCA, possibly through increased binding of
IL-6/sIL-6R with subsequent activation of gp130. With
evidence accumulating about the role of immune activation
in causing neuropathic pain, IL-6 transsignaling, as well
as other cytokine interactions warrants further attention in
CIPN research.
The biological measures, IL-6 and sIL-6R, were nega-
tively correlated with most QOL subscales on the SF-36
Health Survey whereas sgp130 was positively correlated with
mostsubscales.TheseﬁndingsimplythatasIL-6increasesits
capability to activate gp130 via IL-6 transsignaling, health-
related QOL declines. With a potential inﬂuence on physical,
social,andemotionalfunctioning,symptomresearchersmay
wish to consider evaluating the inﬂuence of IL-6 activity on
cooccuring symptoms in cancer.
The ﬁndings of this study inform nurses that persistent
CIPN symptoms and reduced QOL may be related to the
inﬂammatory mediator, IL-6, and increased levels of its solu-
ble receptor. Diligent assessment of neurological functioning
and QOL over the disease trajectory and in survivorship is
required to identify and assist those at risk of experiencing
persistent symptoms. The results also support the need
to examine cytokine interactions throughout the treatment
trajectory in women with BCA in order to determine
the eﬀect on painful CIPN, QOL, and possibly other co-
occurringsymptoms.Longitudinalimmunedatacategorized
by the type of chemotherapeutic agent(s) administered may
provide valuable information on the interactions that lead
to painful CIPN and reduced health-related QOL, as well
as factors which predispose individuals to experiencing
persistent symptoms in survivorship.
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